ARHGAP20 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA558398-Each-of-1 | In Stock | ₹ 48,905.50 |
PIPA558398 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 48,905.50
GST (18%): ₹ 8,802.99
Total Price: ₹ 57,708.49
Antigen
ARHGAP20
Classification
Polyclonal
Conjugate
Unconjugated
Gene
ARHGAP20
Gene Alias
6530403F17Rik; A530023E23Rik; Arhgap20; KIAA1391; mKIAA1391; RA and RhoGAP domain containing protein; RA and RhoGAP domain-containing protein; RARhoGAP; Rho GTPase activating protein 20; rho GTPase activating protein 20 variant 2; rho GTPase-activating protein 20; RhoGTPase activating protein; Rho-type GTPase-activating protein 20
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
57569
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunohistochemistry
Concentration
0.1 mg/mL
Formulation
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2
Gene Accession No.
Q9P2F6
Gene Symbols
ARHGAP20
Immunogen
Recombinant protein corresponding to Human ARHGAP20
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Immunogen sequence: KGPRTHRRCS EPNIEDQNRK LTYLRGIYSK KQHKTSCEAG LLHGEEDYLK RHKSLQMEGQ KLINQSLVMG IEVGKSSATN QNTE Highest antigen sequence identity to the following orthologs: Mouse - 77%, Rat - 86%
- ARHGAP20 is a potent GTPase-activating protein (GAP) and convert Rho-type GTPases into an inactive GDP-bound state
- It contains a pleckstrin homology (PH) domain, a Ras-associating domain, a Rho-GAP domain and two Annexin-like (ANXL) repeats
- ARHGAP20 is a direct downstream target of Rap1 in the neurite outgrowth while it's over expression leads to inactivation of Rho for promoting the neurite outgrowth in a Rap1-dependent manner
- ARHGAP20 is a tumor suppressor gene and is inactivated by deletion in breast cancer and also by chromosomal translocation in B-cell chronic lymphocytic leukemia
- Reports suggest that it may take part in rearrangements of the cytoskeleton and cell signaling events that occur during spermatogenesis
- It is expressed predominantly in human brain, liver, ovary and spinal cord while low expression is found in lymph nodes and fetal liver.